Eli Lilly reported fourth-quarter revenue of $9.35 billion, beating estimates of $8.93 billion. Adjusted earnings per share were $2.49, topping expectations of $2.22. Sales of Eli Lilly's new weight loss drug Zepboud, which launched in November 2023, were $175.8 million. Revenue was boosted by higher prices for Eli Lilly's blockbuster diabetes drug Mounjaro. Mounjaro sales were $2.21 billion, up from just $279.2 million from the same period a year ago. Eli Lilly's stock surged nearly 60% last year due to the soaring demand for its weight loss drugs, variable insurance coverage, and some adverse effects.
